Ironshore Pharmaceuticals
Ironshore Pharmaceuticals is a private specialty pharmaceutical company headquartered in Morrisville, NC, developing and commercializing differentiated ADHD treatments such as JORNAY PM, an evening-dosed methylphenidate therapy, for patients and healthcare providers.
- Company typePublic
- Founded2008
- HeadquartersMorrisville, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ironshore Pharmaceuticals does
Ironshore Pharmaceuticals Inc. is a privately held specialty pharmaceutical company founded in 2008 and headquartered in Morrisville, North Carolina. The company's stated mission is to develop treatment options that improve the lives of patients, with a therapeutic focus evidenced by its ADHD product franchise, including JORNAY PM, a methylphenidate-based treatment distinguished by its evening-dosing profile. The firm employs between 101 and 250 people and operates a full commercial-stage organization led by a CEO (Stephanie Read), Chief Commercial Officer (Danny Villeneuve), Chief Scientific Officer (Bev Incledon), Chief Medical Officer (Lewis Warrington), Chief Information Officer (Tim Branz), and Chief People Officer (Micheal Westphall).
The company's core product technology centers on proprietary drug formulations targeting central nervous system / ADHD indications. Its flagship commercial product, JORNAY PM, was the first and only evening-dosed methylphenidate treatment available in Canada as of its October 2025 launch there via a partnership with Knight Therapeutics, signaling a partner-driven international commercialization model rather than standalone international infrastructure. In January 2017, the company raised $200,000,000 in a financing round led by Morgan Stanley, indicating substantial institutional backing consistent with a commercial-stage specialty pharma scaling its revenue base.
Ironshore's revenue model is not directly disclosed in the available source material, but is consistent with a specialty pharmaceutical commercial model: sales of FDA-approved prescription medications to patients via prescribers and pharmacy benefit managers, supplemented by international out-licensing/distribution partnerships (such as Knight Therapeutics for Canada) to extend geographic reach without building parallel commercial organizations. Customer concentration risk appears low at the end-patient level but moderate at the international-distribution-partner level for Canada. No specific AI/ML capabilities are evident in the disclosed information, with competitive differentiation resting on drug formulation know-how, regulatory approvals, and commercial execution in ADHD therapeutics.
Ironshore Pharmaceuticals firmographics
Firmographics- Name
- Ironshore Pharmaceuticals
- Legal name
- Collegium Pharmaceutical, Inc.
- Website
- https://ironshorepharma.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Ironshore Pharmaceuticals is a private specialty pharmaceutical company headquartered in Morrisville, NC, developing and commercializing differentiated ADHD treatments such as JORNAY PM, an evening-dosed methylphenidate therapy, for patients and healthcare providers.
- Ownership category
- akta.pro rank
Ironshore Pharmaceuticals industry classification
Industry- Product category
- ADHD Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Ironshore Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Morrisville
- HQ country
- United States
- HQ region
- North America
Markets served
Ironshore Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Ironshore Pharmaceuticals product offering
Product offeringCore offering
Ironshore Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for serious neurological conditions, with a portfolio centered on ADHD (attention deficit hyperactivity disorder). Its differentiated products include evening-dosed methylphenidate formulations designed to address unmet needs in ADHD symptom management across the day.
Product overview
Collegium Pharmaceutical is a diversified biopharmaceutical company with a portfolio of differentiated medications to treat serious medical conditions. The company is building a leading position in the ADHD treatment space, having acquired AZSTARYS® from Corium Therapeutics in May 2026, complementing their existing product portfolio. Their approach emphasizes leading with science to support people living with serious medical conditions and the healthcare professionals caring for them.
Differentiator
Problem solved
Functional benefit
Products and services
- JORNAY PM Evening-dosed methylphenidate treatment for ADHD, designed to provide symptom control from morning through the day. Targeted at patients with attention deficit hyperactivity disorder and prescribed by healthcare professionals.
- AZSTARYS A differentiated medication for the treatment of ADHD, acquired by Collegium Pharmaceutical from Corium Therapeutics in May 2026 to complement the ADHD portfolio.
Companies that use Ironshore Pharmaceuticals
Customer profileIdeal customer profiles1 record
Ironshore Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ironshore Pharmaceuticals partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Ironshore Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Supernus Pharmaceuticals: Specialty CNS pharmaceutical company focused on ADHD treatments (e.g., Qelbree) and other CNS products. Directly comparable to Ironshore as a CNS/ADHD-focused branded specialty pharma with differentiated dosing technology.
- Corium Therapeutics: CNS-focused specialty pharma that developed and commercialized AZSTARYS, which Collegium acquired from Corium in May 2026. Closely comparable as an ADHD specialty pharmaceutical developer with branded stimulant assets.
- Tris Pharma: Private specialty pharma focused on ADHD and other CNS products, known for extended-release/liquid stimulant formulations. Comparable technology platform to Ironshore's extended-release methylphenidate work.
- Rhodes Pharmaceuticals: Specialty/generic pharmaceutical company with ADHD stimulant product portfolio. Comparable as a competitor in the methylphenidate ADHD market with overlapping prescriber base.
- Noven Pharmaceuticals: Specialty pharmaceutical company with CNS/ADHD transdermal and oral products. Comparable as a CNS-focused specialty pharma with differentiated ADHD delivery technology.
- Neos Therapeutics: Specialty pharmaceutical company developing extended-release ADHD medications (e.g., Adzenys XR-ODT). Directly comparable as a smaller ADHD-focused branded specialty pharma with extended-release technology.
- Collegium Pharmaceutical: Publicly traded specialty pharmaceutical company (NASDAQ: COLL) focused on CNS and pain products that has acquired Ironshore assets. Closely tied as the acquirer/integrator of the JORNAY PM franchise.
Broad incumbents
- Takeda Pharmaceutical (Vyvanse franchise): Large pharmaceutical company commercializing Vyvanse, a leading branded ADHD medication. Comparable as a major player in the same ADHD therapeutic category with overlapping patient population.
- Janssen Pharmaceuticals (Concerta): Johnson & Johnson subsidiary marketing Concerta (extended-release methylphenidate). Directly comparable as a major extended-release methylphenidate product in the same ADHD market.
- Eli Lilly (Strattera): Large pharmaceutical company marketing Strattera for ADHD. Comparable as a major branded ADHD player with overlapping patient/prescriber base, though broader portfolio beyond ADHD.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Ironshore Pharmaceuticals social profiles
Digital presenceIronshore Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ironshore Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Ironshore Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ironshore Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ironshore Pharmaceuticals
What does Ironshore Pharmaceuticals do?
Ironshore Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for serious neurological conditions, with a portfolio centered on ADHD (attention deficit hyperactivity disorder). Its differentiated products include evening-dosed methylphenidate formulations designed to address unmet needs in ADHD symptom management across the day.
Is Ironshore Pharmaceuticals a public or private company?
Ironshore Pharmaceuticals is a public company. It is classified as corporate owned and is currently operating.
When was Ironshore Pharmaceuticals founded?
Ironshore Pharmaceuticals was founded in 2008. It employs 101 to 250 people.
Where is Ironshore Pharmaceuticals based?
Ironshore Pharmaceuticals is headquartered in Morrisville, United States, in the North America region.
Who are Ironshore Pharmaceuticals's main competitors?
Direct peers on record are Supernus Pharmaceuticals, Corium Therapeutics, Tris Pharma, Rhodes Pharmaceuticals, Noven Pharmaceuticals, Neos Therapeutics and Collegium Pharmaceutical. Broad incumbents are Takeda Pharmaceutical (Vyvanse franchise), Janssen Pharmaceuticals (Concerta) and Eli Lilly (Strattera).
Does Ironshore Pharmaceuticals have an API?
No public API is recorded for Ironshore Pharmaceuticals.
What industry is Ironshore Pharmaceuticals in?
Ironshore Pharmaceuticals's product category is ADHD Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.